Celltrion’s head of strategy and operations, Ho Ung Kim, told reporters this week that the intravenous Herzuma could be launched at as much as a 50% discount to a subcutaneously administered presentation of the reference Herceptin.
Celltrion announced on Tuesday that the European Commission (EC) has granted a marketing authorization for Herzuma, Celltrion’s biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive early breast cancer, metastatic breast cancer, or metastatic gastric cancer.
Final approval of the biosimilar follows a December 2017 positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use. The EC’s decision allows Herzuma to be marketed in the 28 member states of the European Union, as well as in Norway, Liechtenstein, and Iceland.
“The development of [biosimilars] is of great importance in the field of oncology, and has the potential to enrich our therapeutic arsenal against a variety of diseases and to increase patients’ accessibility to innovative drugs at a more affordable price,” said Woo Sung Kee, CEO of Celltrion.
While a launch date for the biosimilar has not yet been announced, a representative from Celltrion Healthcare, Celltrion’s marketing arm, told Korean media in 2017 that Herzuma could be launched in Europe as soon as 3 months following EC approval. Celltrion’s head of strategy and operations, Ho Ung Kim, told reporters this week that the intravenous Herzuma could be launched at as much as a 50% discount to a subcutaneously administered presentation of the reference Herceptin.
Celltrion also filed a Biologics License Application for the trastuzumab biosimilar with the FDA in July 2017, but recent regulatory challenges have put a potential US approval date into question; while a regulatory decision on Herzuma was expected in March 2018, Celltrion received a warning letter from the FDA on January 30 that raised issues with the company’s manufacturing practices.
In a February 1 statement on the letter, Celltrion said that the warning did not impact the company’s ability to make its biosimilar infliximab, Inflectra, but did not disclose how the warning would impact Herzuma. However, Celltrion’s partner, Teva, told investors that FDA approval of both Herzuma and a proposed rituximab biosimilar would likely be delayed while Celltrion remediates the issues at the facility.
The company also faces ongoing legal challenges for Herzuma in the United States; Celltrion and Teva have filed a lawsuit against Genentech (sponsor of the reference Herceptin) in a California district court, seeking a declaratory judgment that 38 patents covering Herceptin are invalid, unenforceable, or not infringed by Celltrion’s product. The patents include those addressing methods of production, dosage, methods of treatment, and extending time to disease progression, among others.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
2 Commerce Drive
Cranbury, NJ 08512